Apexigen
summary of program | Apexigen
Company
Deck Type
Sector
Industry
Deck date
March 2022
Slide
18 of 28
Related slides by other companies
argenx SE
Results
October 2021
deep antibody pipeline of differentiated candidates data | argenx SE
ATAI
Investor Presentation
October 2022
demonstrated pro cognitive treatment for developed product in licensed with extensive clinical clinical data package human phase data show replicated clinically significant learning and memory effects consistent with broad clinical pro cognitive data well tolerated subjects dosed centrally acting oral drug initial indication cognitive impairment associated with schizophrenia is characterized by episodic learning and memory deficits no approved treatment a risked excellent tolerability | ATAI
Chimerix
Investor Presentation
May 2023
multiple unique aspects to data support translation to phase success | Chimerix
Kymera
Results
December 2022
interim safety data summary | Kymera
Other recent decks by Apexigen
See all presentations (2 decks)
Investor Presentation
September 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights